Main parameters of the patient, before the introduction of biologics, at the switch to mepolizumab, and after 3 months of therapy
Main parameters
Baseline
After 5 weeks
At switch
After 3 months of mepolizumab
Blood eosinophils
500 cells/µl
6,600 cells/µl
1,900 cells/µl
100 cells/ µl
FeNO
57 ppb
22 ppb
38 ppb
29 ppb
FEV1 (%)
45%
56%
51%
62%
FEV1 (L)
1.15 L
1.43 L
1.30 L
1.55 L
ACT
18
23
25
24
SNOT-22
58
28
20
24
Parameters of principal markers, found during single observations, concerning lung function tests and control of the disease before the first biologic used, dupilumab (baseline), after 5 weeks of treatment with dupilumab, at the switch to mepolizumab and after 3 months from the first administration of 300 mg of mepolizumab. FEV1: forced expiratory volume in 1 second; ACT: asthma control test; SNOT-22: sinonasal outcome test-22
Declarations
Author contributions
DB, BB: Conceptualization, Investigation, Writing—original draft. VC, FRMC, CDT, SF, VM, MM, MR, MB: Supervision, Validation. FB: Writing—review & editing, Validation, Supervision. All authors read and approved the submitted version.
Conflicts of interest
Diego Bagnasco who is the Editorial Board Member and Fulvio Braido who is the Associate Editor of Exploration of Asthma & Allergy had no involvement in the decision-making or the review process of this manuscript. The other authors declare that there are no conflicts of interest.
Ethical approval
The study was approved by the Genoa Ethics Committee (EC 2017, ID 3663) and complies with the Declaration of Helsinki.
Consent to participate
Informed consent to participate in the study was obtained from the patient.
Consent to publication
Informed consent to publication was obtained from relevant participants.
Availability of data and materials
The data of this manuscript could be available from the corresponding authors upon reasonable request.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges.J Asthma Allergy. 2016;9:45–53. [DOI] [PubMed] [PMC]
Berger P, Menzies-Gow A, Peters AT, Kuna P, Rabe KF, Altincatal A, et al. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.Ann Allergy Asthma Immunol. 2023;130:215–24. [DOI] [PubMed]
Bagnasco D, Bondi B, Brussino L, Nicola S, Cameli P, Tiotiu A, et al.; On Behalf Of The Sani Group. Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab.J Pers Med. 2025;15:43. [DOI] [PubMed] [PMC]
Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.Nat Rev Rheumatol. 2023;19:378–93. [DOI] [PubMed]
Caminati M, Olivieri B, Dama A, Micheletto C, Paggiaro P, Pinter P, et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management.Expert Rev Respir Med. 2022;16:713–21. [DOI] [PubMed]
Strong A, Lin T, Sverrild A, Mackay A, Lee J, Zubrinich C, et al. Dupilumab-associated hypereosinophilia in severe asthma.ERJ Open Res. 2024;10:00048-2024. [DOI] [PubMed]
Ryser FS, Yalamanoglu A, Valaperti A, Brühlmann C, Mauthe T, Traidl S, et al. Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis.Allergy. 2023;78:2712–23. [DOI] [PubMed]
Martins-Martinho J, Pereira da Costa R, Abreu T, Ponte C. Successful combination therapy of mepolizumab and dupilumab in a patient with EGPA: a future therapeutic option?Rheumatol Adv Pract. 2024;8:rkae093. [DOI] [PubMed] [PMC]
Ezekwe E, Weskamp A, Khoury P, Constantine G, Boggs N, Klion A, et al. Dupilumab Use in Patients with Hypereosinophilic Syndrome: A Multi-Center Case Series.Journal of Allergy and Clinical Immunology. 2024;153:AB61. [DOI]
Carrón-Herrero A, Pelaia C, Paoletti G. New therapeutic approaches with biological drugs for eosinophilic granulomatosis with polyangiitis.Explor Asthma Allergy. 2023;1:31–48. [DOI]
Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.N Engl J Med. 2017;376:1921–32. [DOI] [PubMed] [PMC]
Wechsler ME, Silver J, Stone B, Huynh L, da Costa Jr W, Ye M, et al. Real-world Mepolizumab Use in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Demonstrates Improvement in End-organ Manifestations and Long-term Corticosteroid Benefit: An Analysis of Allergy Practices in the United States.AM J RESP CRIT CARE. 2024;209:A5363. [DOI]
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, et al.; MANDARA Study Group. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.N Engl J Med. 2024;390:911–21. [DOI] [PubMed]
